Skip to main content
SpringerLink
Log in

Major Advances in Hepatitis C Treatment but Not Hepatitis B

  • Chapter
  • First Online:
Current Trends and Concerns in Infectious Diseases

Part of the book series: Emerging Infectious Diseases of the 21st Century ((EIDC))

Abstract

Hepatitis B and hepatitis C viruses are among the most common chronic endemic pathogens of humans worldwide with more than 500 million people infected globally. Both pathogens can cause acute or chronic hepatitis that can progress to liver cirrhosis and lead to hepatocellular cancer (liver cancer). Viral hepatitis mortality and morbidity have increased since 1990–2013 by 63% and 34%, respectively, mainly by hepatitis B and C infections. Tremendous advances in the treatment of hepatitis C have been achieved within the past decade or less with novel direct antiviral agents that are well tolerated and elicit long-term viral suppression or cure in over 95% of infected subjects with just 2–3 months therapy. Thus, potentially eradication of hepatitis C from humans worldwide is an achievable goal. Treatment for chronic hepatitis B virus has been available for over two decades, but therapy is not curative and significant therapeutic advances have not been realized. This chapter reviews the biology and pathogenesis of the two viruses and discusses current available therapies and future trends.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Stanaway JD, Flaxman AD, Naghavi M et al (2016) The global burden of viral hepatitis from 1990 to 2013. Lancet 388:1081–1088. https://doi.org/10.1016/S0140-6736[16]30579-7.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Hepatitis B Foundation: history of hepatitis B vaccine. http://www.hepb.org/prevention-and-diagnosis/vaccination/history-of-hepatitis-b-vaccine/

  3. Trepo C, Chan HL, Lok A (2014) Hepatitis B virus infection. Lancet 384:2053–2063

    Article  CAS  PubMed  Google Scholar 

  4. Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL (2012) Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology 56:422–433

    Article  PubMed  Google Scholar 

  5. WHO (1999) Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the viral Hepatitis Prevention board, Antwerp, Belgium. J Viral Hepat 6:35–47

    Article  Google Scholar 

  6. Centers for Disease Control and Prevention. Viral hepatitis C information. Overview and statistics. 2017. www.cdc.gov/hepatitis/hcv/hcvfag.htm#section1. Accessed 18 March 2017

  7. Centers for Disease Control and Prevention. Viral hepatitis-hepatitis C information. Hepatitis C FAQs for health professionals. www.cdc.gov/hepatitis/hcv/hcvfaq.htm. Accessed 15 March 2017

  8. Dandri M, Locarnini S (2012) New insights in the pathobiology of hepatitis B virus infection. Gut 61(suppl 1):6–17

    Article  CAS  Google Scholar 

  9. Marusawa H, Uemoto S, Hijikata M et al (2000) Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 31:488

    Article  CAS  PubMed  Google Scholar 

  10. Yuki N, Nagaoka T, Yamashiro M et al (2003) Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 37:1172

    Article  CAS  PubMed  Google Scholar 

  11. Kennedy PT, Sandalova E, Jo J et al (2012) Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 143:637–645

    Article  CAS  PubMed  Google Scholar 

  12. Wong GLH, Wong VWS, Chan HLY (2016) Virus and host testing to manage chronic hepatitis B. Clin Infect Dis 62(S4):S298–S305

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH (2015) AASLD guidelines for treatment of chronic hepatitis B. Hepatology 63:261–283. https://doi.org/10.1002/hep.28156

    Article  PubMed  Google Scholar 

  14. Seto WK, Wong DK, Fung J et al (2014) Linearized hepatitis B surface antigen and hepatitis B core-related antigen in the natural history of chronic hepatitis B. Clin Microbiol Infect 20:1173–1180

    Article  CAS  PubMed  Google Scholar 

  15. Huo TI, Wu JC, Lee PC et al (1998) Seroclearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology 28:231–236

    Article  CAS  PubMed  Google Scholar 

  16. Liaw YF, Chen YC, Sheen IS, Chien RN, Yeh CT, Chu CM (2004) Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 126:1024–1029

    Article  PubMed  Google Scholar 

  17. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ (2006) Predicting cirrhosis risk based on the circulating hepatitis B viral load. Gastroenterology 130:678–686

    Article  PubMed  Google Scholar 

  18. Yang H, Lu S, Liaw Y et al (2002) Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 347:168–174

    Article  CAS  PubMed  Google Scholar 

  19. Chen CJ, Yang HI, Su J et al (2006) Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B viral load. JAMA 295:65–73

    Article  CAS  PubMed  Google Scholar 

  20. Fattovich G (2003) Natural history and prognosis of hepatitis B. Semin Liver Dis 23:47–58

    Article  PubMed  Google Scholar 

  21. McMahon BJ (2009) Natural history of chronic hepatitis B virus infection. Hepatology 49(5 Suppl):S45–S55

    Article  CAS  PubMed  Google Scholar 

  22. Flores R, Ruiz-Ruiz S, Serra P (2012) Viroids and the hepatitis delta virus. Semin Liver Dis 32:201–210

    Article  CAS  PubMed  Google Scholar 

  23. Terrault NA, Dodge JL, Murphy EL et al (2013) Sexual transmission of hepatitis C virus among monogamous heterosexual couples: the HCV partners study. Hepatology 13:881–889

    Article  Google Scholar 

  24. Wilkin T (2015) Primary care for men who have sex with men. N Engl J Med 373:854–862

    Article  CAS  PubMed  Google Scholar 

  25. Foster AL, Gaisa MM, Hijdra RM, Morey TJ, Jacobson KB, Fierer DS (2017) Shedding of hepatitis C virus into the rectum of HIV-infected men who have sex with men. Clin Infect Dis 64:284–288

    Article  CAS  PubMed  Google Scholar 

  26. Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ (2014) Vertical transmission of hepatitis c virus: systematic review and meta-analysis. Clin Infect Dis 59:765–773

    Article  PubMed  PubMed Central  Google Scholar 

  27. Maheshwari A, Ray S, Thuluvath PJ (2008) Acute hepatitis C. Lancet 372:321–332

    Article  PubMed  Google Scholar 

  28. Grebely J, Page K, Sacks-Davis R et al (2014) The effects of female sex, viral genotype, and IL288 genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology 59:109–120

    Article  CAS  PubMed  Google Scholar 

  29. Kim A (2016) Hepatitis C virus. Ann Intern Med 165:33–47

    Article  Google Scholar 

  30. Tapper EB, Afdhal NH (2013) Is 3 the new 1: perspective on virology, natural history and treatment for hepatitis C genotype 3. J Viral Hepat 20:669–677

    Article  CAS  PubMed  Google Scholar 

  31. Kandathil AJ, Thomas DL, Balagopal A (2018) Presence of human hepgivirus-1 in a cohort of people who inject drugs. Ann Intern Med 168:158–159

    Article  PubMed  Google Scholar 

  32. Delaney WE IV (2013) Molecular virology of chronic hepatitis B and C: parallels, contrasts and impact on drug development and treatment outcome. Antivir Res 99:34–48

    Article  CAS  PubMed  Google Scholar 

  33. Dnandri M, Petersen J (2016) Mechanism of hepatitis B virus persistence in hepatocytes and its carcinogenic potential. Clin Infect Dis 62(S4):S281–S288

    Article  CAS  Google Scholar 

  34. Chen MT, Billaud JN, Sallberg M, Guidotti LG, Chisari FV, Jones J, Hughes J, Milich DR (2004) A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci U S A 101:14913–14918

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Murphy DG, Sablon E, Chamberland J, Fournier E, Dandavino R, Tremblay CL (2015) Hepatitis c virus genotype 7, a new genotype originating from central Africa. J Clin Microbiol 53:967–972

    Article  PubMed  PubMed Central  Google Scholar 

  36. Boprgia SM, Hedskog C, Parthy B et al (2018) Identification of a novel hepatitis C virus genotype from Punjab, India: expanding classification of hepatitis C virus into 8 genotypes. J Infect Dis 218(11):1722–1729

    Article  Google Scholar 

  37. McCaffey AP, Nakai H, Pandey K et al (2003) Inhibition of hepatitis B virus in mice by RNA interference. Nat Biotechnol 21:639–644

    Article  Google Scholar 

  38. Morissey DV, Lockeridge JA, Shaw L et al (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002–1007

    Article  CAS  Google Scholar 

  39. Petersen J, Danderi M, Mier W et al (2008) Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol 26:335–341

    Article  CAS  PubMed  Google Scholar 

  40. Yoshio S, Kanto T (2016) Host-virus interactions in hepatitis B and hepatitis C infection. J Gastroenterol 51:409–420

    Article  CAS  PubMed  Google Scholar 

  41. Lucifora J, Xia Y, Reisinger F et al (2014) Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343:1221–1228

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Yoshio S, Sugiyama M, Shoji H et al (2016) Indolamine-2,3-dioxygenase as an effector and indicator of protective immune responses in patients with acute hepatitis B. Hepatology 63:83–94

    Article  CAS  PubMed  Google Scholar 

  43. Khakoo SI, Thio CL, Martin MP et al (2004) HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305:672–674

    Article  CAS  Google Scholar 

  44. Klenerman P, thimme R (2012) T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 61:1226–1234

    Article  CAS  PubMed  Google Scholar 

  45. Seifert U, Liermann H, Racanelli V et al (2004) Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest 114:250–259

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Janssen HLA, van Zonneeveld M, Seturk H, HBV 99-01 Study Group et al (2005) Pegylated interferon alfa-2b alone and in combination with lamivudine for HBeAg-positive chronic Hepatitis B: a randomized trial. Lancet 365:123–129

    Article  CAS  PubMed  Google Scholar 

  47. Lau GK, Piratvisuth T, Luo X et al (2005) Peginterferon Alfa-2a HBeAg-Positive Chronic Hepatitis B Study Group. Peginterferon alfa-2a, lamivudine and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352:2682–2695

    Article  CAS  PubMed  Google Scholar 

  48. Buster EH, Flink HJ, Cakaloglu Y et al (2008) Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 135:459–467

    Article  CAS  PubMed  Google Scholar 

  49. Marcellin P, Bonino F, Lau GK et al (2009) Sustained response of hepatitis B e-antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 136:2169–2179

    Article  CAS  PubMed  Google Scholar 

  50. Buster EH, Hansen BE, Lau GK et al (2009) Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 136:2002–2009

    Article  CAS  Google Scholar 

  51. Sonneveld MJ, Hansen BE, Piratvisuth T et al (2013) Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 58:872–880

    Article  CAS  PubMed  Google Scholar 

  52. Lampertico P, Viogano M, Cheroni C et al (2013) IL128 polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 57:890–896

    Article  CAS  PubMed  Google Scholar 

  53. Liaw YE (2011) Impact of hepatitis B therapy on the long-term outcome of liver disease. Liver Int 31(Suppl 1):117–121

    Article  PubMed  Google Scholar 

  54. Lai CL, Yuen MF (2013) Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology 57:399–408

    Article  CAS  PubMed  Google Scholar 

  55. Chang TT, Liaw YF, Wu SS et al (2010) Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 52:886–893

    Article  CAS  PubMed  Google Scholar 

  56. Marcellin P, Gane E, Buti M et al (2013) Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open label follow-up study. Lancet 381:468–475

    Article  CAS  PubMed  Google Scholar 

  57. Chang Y, Choe WH, Sinn DH et al (2017) Nucleos[t]ide analogue treatment for patients with hepatitis B virus [HBV] e antigen-positive chronic HBV genotype C infection: a nationwide, multicenter, retrospective study. J Infect Dis 216:1407–1414

    Article  CAS  PubMed  Google Scholar 

  58. Nguyen MH, Yang H-I, Le A et al (2019) Reduced incidence of hepatocellular carcinoma in cirrhotic and noncirrhotic patients with chronic hepatitis B treated with tenofovir—a propensity score-matched study. J Infect Dis 219:10–18

    Article  PubMed  Google Scholar 

  59. Su T, Yang HC, Tseng TC et al (2018) Distinct relapse rates and risk prediction after discontinuating tenofovir and entecavir therapy. J Infect Dis 217:1193–1201

    Article  CAS  PubMed  Google Scholar 

  60. Zu Siederdissen CH, Rinker F, Maasoumy B et al (2016) Viral and host responses after stopping long-term nucleos[t]ide analogue in HBeAg-negative chronic hepatitis B. J Infect Dis 214:1492–1497

    Article  CAS  Google Scholar 

  61. Jeng WJ, Sheen IS, Chen YC et al (2013) Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 58:1888–1896

    Article  CAS  PubMed  Google Scholar 

  62. Bedre RH, Raj U, Miosra SP, Varadwaj PK (2016) Antiviral therapy with nucleoside/nucleotide analogues in chronic hepatitis B: a meta-analysis of prospective randomized trials. Indian J Gastroenterol 35:75–82

    Article  PubMed  Google Scholar 

  63. Jonas MM, Lok AS, McMahon BJ et al (2016) Antiviral therapy in management of chronic hepatitis B viral infection in children: a systematic review and meta-analysis. Hepatology 63:307–318

    Article  CAS  PubMed  Google Scholar 

  64. Chi H, Wong D, Peng J et al (2017) Durability of response after hepatitis B surface antigen seroclearance during nucleos[t]ide analogue treatment in a multiethnic cohort of chronic hepatitis patients: results after treatment cessation. Clin Infect Dis 65:680–683

    Article  PubMed  Google Scholar 

  65. Wei W, Wu Q, Zhou J, Kong Y, You H (2015) Better antiviral efficacy found in nucleos[t]ide analog [NA] combination with interferon therapy than NA monotherapy for HBeAg positive chronic hepatitis B: a meta-analysis. Int J Environ Res Public Health 12:10039–10055

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. Xie QL, Zhu Y, Wu LH, Fu LL, Xiang Y (2015) The efficacy and safety of entecavir and interferon combination therapy for chronic hepatitis B virus infection: a meta-analysis. PLoS ONE 10:e132219

    Google Scholar 

  67. Marcellin P, Ahn SH, Ma X et al (2016) Combination of tenofovir disoproxil fumarate and peginterferon α-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B. Gastroenterology 150:134–144

    Article  CAS  PubMed  Google Scholar 

  68. Paul S, Dickstein A, Saxena A et al (2017) Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematological malignancy: a meta-analysis. Hepatology 66:379–388

    Article  CAS  PubMed  Google Scholar 

  69. Hyun MH, Lee YS, Kim JH et al (2017) Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. Ailment Pharmacol Ther 45:1493–1505

    Article  CAS  Google Scholar 

  70. Cheng G, Wang C, Chen J et al (2017) Hepatitis B reactivation in hepatitis C coinfected patients treated with antiviral agents. Hepatology 66:13–26

    Article  CAS  Google Scholar 

  71. Yurdaydin C, Keskin O, Kalkan C et al (2018) Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease. J Infect Dis 217:1184–1192

    Article  CAS  PubMed  Google Scholar 

  72. Veldt BJ, Heathcote EJ, Wedemeyer H et al (2007) Sustained virological response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 147:677–684

    Article  PubMed  Google Scholar 

  73. Van der Meer AJ, Veldt BJ, Feld JJ et al (2012) Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 308:2584–2593

    Article  PubMed  Google Scholar 

  74. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Yitter Y (2013) Eradication of hepatitis C virus and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 158:3239–3237

    Article  Google Scholar 

  75. Bulteel N, Sarathy P, Forrest P et al (2016) Factors associated with spontaneous clearance of chronic hepatitis C virus infection. J Hepatol 65:266–272

    Article  PubMed  Google Scholar 

  76. Hashem M, Jhaveri R, Saleh DA et al (2017) Spontaneous viral load and subsequent clearance of chronic hepatitis C virus in postpartum women correlates with favorable interleukin-28B gene allele. Clin Infect Dis 65:999–105

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. McCauley JA, Rudd MT (2016) Hepatitis C virus NS3/4A protease inhibitors. Curr Opin Pharmacol 30:84–92

    Article  CAS  PubMed  Google Scholar 

  78. Gitto S, Gamal N, Andreone P (2017) NS5A inhibitors for the treatment of hepatitis C infection. J Viral Hepat 24:180–186

    Article  CAS  PubMed  Google Scholar 

  79. Eltahla AA, Luciani F, White PA, Lloyd AR, Bull RA (2015) Inhibitors of the hepatitis C virus polymerase; mode of action and resistance. Viruses 7:5206–5224

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Buti M, Riveiro-Barciela M, Esteban R (2015) Management of direct-acting antiviral agent failures. J Hepatol 63:1511–1522

    Article  PubMed  Google Scholar 

  81. Benitez-Gutierrez L, Barreiro P, Labarga P et al (2016) Prevention and management of treatment failure to new oral hepatitis C drugs. Expert Opin Pharmacother 17:1215–1233

    Article  CAS  PubMed  Google Scholar 

  82. Johnson S, Thompson D, Raccor B (2017) Hepatitis C virus genotype 3: update on current and emergent therapeutic interventions. Curr Infect Dis Rep 19:22

    Article  PubMed  Google Scholar 

  83. Soriano V, Fernandez-Montero JV, de Mendoza C, Benitez-Gutierrez L, Pena JM, Arias A, Barreiro P (2017) Treatment of hepatitis C with new fixed dose combinations. Expert Opin Pharmacother 18:1235–1242

    Article  CAS  PubMed  Google Scholar 

  84. European Association for the Study of the Liver (2017) EASL recommendations on treatment of hepatitis C 2016. J Hepatol 66:153–194

    Article  Google Scholar 

  85. Falade-Nwulia O, Suarez-Cuervo C, Nelson DR, Fried MW, Segal JB, Sulkowski MS (2017) Oral direct-acting agent therapy for hepatitis C virus infection. Ann Intern Med 166:637–648

    Article  PubMed  PubMed Central  Google Scholar 

  86. IDSA/AASLD. Recommendations for testing, managing, and treating hepatitis C. Updated September 21, 2017. Available from http://www.hcvguidelines.org. Accessed February 12, 2018

  87. Zeuzem S, Wand FS, Asatryan A et al (2018) Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med 378:354–369

    Article  CAS  PubMed  Google Scholar 

  88. Brown RS, Hezode C, Wong S, et al Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with genotype 1-6 infection and compensated cirrhosis: the EXPEDITION-8 study. Program and abstracts of the American Association for the Study of Liver Dioseases; Nov. 9–13, 2018; San Francisco, California

    Google Scholar 

  89. Foster GR, Irving WL, Cheung MC et al (2016) Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64:1224–1231

    Article  CAS  PubMed  Google Scholar 

  90. Cheung MC, Walter AJ, Hudson BE et al (2016) Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65:741–747

    Article  CAS  PubMed  Google Scholar 

  91. Alter MJ (2006) Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44(suppl 1):S6–S9

    Article  PubMed  Google Scholar 

  92. Sogni P, Gilbert C, Lacombe K et al (2016) All-oral direct-acting antiviral regimens in HIV/hepatitis C virus-coinfected patients with cirrhosis are efficient and safe: real-life results from the prospective ANR CO13-HEPAVIH Cohort. Clin Infect Dis 63:763–770

    Article  CAS  PubMed  Google Scholar 

  93. MacBrayne CE, Kiser JJ (2016) Pharmacological considerations in the treatment of hepatitis C virus in persons with HIV. Clin Infect Dis 63(S1):S12–S23

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Fabrizi F, Verdesca S, Messa P, Martin P (2015) Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci 60:3801–3813

    Article  PubMed  Google Scholar 

  95. Lee JJ, Lin MY, Chang JS et al (2014) Hepatitis C virus increases the risk of developing end-stage renal disease using competing risk analysis. PLoS One 9:e100790

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  96. Desnoyer A, Pospai D, Le MP et al (2016) Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C. J Hepatol 65:40–47

    Article  CAS  PubMed  Google Scholar 

  97. Nazario HE, Ndunu M, Modi AA (2016) Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with endstage renal disease on hemodialysis or GFR <30ml/min. Liver Int 36:798–801

    Article  CAS  PubMed  Google Scholar 

  98. Roth D, Nelson DR, Bruchfeld A et al (2015) Grazoprevir plus elbasvir in treatment of naïve and experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease [the C-SURFER study]: a combination phase 3 study. Lancet 386:1537–1545

    Article  CAS  PubMed  Google Scholar 

  99. Gane E, Lawitz E, Pugatch D et al (2017) Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med 377:1448–1455

    Article  CAS  PubMed  Google Scholar 

  100. Colombo M, Aghemo A, Liu H et al (2017) Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4. Ann Intern Med 166:109–117

    Article  PubMed  Google Scholar 

  101. Nelson PK, Mathers BM, Cowie B et al (2011) Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 378:571–583

    Article  PubMed  PubMed Central  Google Scholar 

  102. Hajarizadeh B, Grebely J, Dore GJ (2013) Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 10:553–562

    Article  CAS  PubMed  Google Scholar 

  103. Dore GJ, Altice F, Litwin AH et al (2016) Elbasvir-grazoprevir to treat hepatitis C virus infection in persons receiving opiod agonist therapy. Ann Intern Med 165:625–634

    Article  PubMed  Google Scholar 

  104. Young J, Rossi C, Gill J et al (2017) Risk factor for hepatitis virus reinfection after sustained virological response in patients coinfected with HIV. Clin Infect Dis 64:1154–1162

    Article  PubMed  PubMed Central  Google Scholar 

  105. Sarrazin C, Isakopv V, Svarovskaia ES et al (2017) Late relapse versus hepatitis C virus reinfection in patients with sustained virological response after sofosbuvir-based therapies. Clin Infect Dis 64:44–52

    Article  CAS  PubMed  Google Scholar 

  106. Sarrazin C (2016) The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 64:486–504

    Article  PubMed  Google Scholar 

  107. Bourliere M, Gordon SC, Flamm SL et al (2017) Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med 376:2134–2146

    Article  CAS  PubMed  Google Scholar 

  108. Poordad F, Pol S, Asatryan A et al (2017) MAGELLAN-1, part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct–acting antiviral treatment failure. Gastroenterology 152:S1057

    Article  Google Scholar 

  109. Poordad F, Feilizarta F, Asatryan A et al (2017) Glecaprevir and pibretasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology 66:389–397

    Article  CAS  PubMed  Google Scholar 

  110. de Ledinghen V, Laforest C, Hezode C et al (2018) Retreatment5 with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed an NS5A- or NS3-containing regimen: The ANRS HC34 REVENGE Study. Clin Infect Dis 66:1013–1018

    Article  PubMed  CAS  Google Scholar 

  111. Jacobsen JC, Nielsen EE, Feinberg J et al (2017) Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev 6:CD012143

    Google Scholar 

  112. Powderly WG, Naggie S, Kim AY, Vargas HE, Chung RT, Lok AS (2017) IDSA/AASLD response to Cochrane Review on direct-acting antivirals for hepatitis C. Clin Infect Dis 65:1773–1775

    Article  PubMed  Google Scholar 

  113. Simmons B, Saleem J, Heath K, Cooke GS, Hill A (2015) Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis 61:730–740

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  114. Butt AA, Yan P, Simon TG, Abou-Samra AB (2017) Effect of paritaprevir/ritonavir/ombitasvir/dasabuvir and ledipasvir/sofosbuvir regimens on survival compared with untreated hepatitis C virus-infected persons: results from ERCHIVES. Clin Infect Dis 65:1006–1011

    Article  CAS  PubMed  Google Scholar 

  115. Calvaruso V, Caribbo G, Caccida I et al (2018) Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology 155:411–421

    Article  CAS  PubMed  Google Scholar 

  116. Woolley AE, Singh SK, Goldberg HJ et al (2019) Heart and lung transplants from HCV-infected donors to uninfected recipients. N Engl J Med 380:1606–1617

    Article  PubMed  PubMed Central  Google Scholar 

  117. Trooskin SB, Reynolds H, Koostman JR (2015) Access to costly new hepatitis C drugs: medicine, money and advocacy. Clin Infect Dis 61:1825–1830

    Article  PubMed  Google Scholar 

  118. Najafzadeh M, Andersson K, Shrank WH et al (2015) Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med 162:407–419

    Article  PubMed  Google Scholar 

  119. da Fonseca EM, Shadlen K, Bastos FI (2019) Brazil’s fight against hepatitis C---universalism, local production, and patients. N Engl J Med 389:605–607

    Article  Google Scholar 

  120. Liang TJ, Block TM, McMahon BJ et al (2015) Present and future therapies of hepatitis B: from discovery to cure. Hepatology 62:1893–1908

    Article  PubMed  Google Scholar 

  121. Cai D, mills C, Yu W et al (2012) Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 56:4277–4288

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Lucifora J, Protzer U (2016) Attacking hepatitis B virus cccDNA—the holy grail to hepatitis B cure. J Hepatol 64:S41–S48

    Article  CAS  PubMed  Google Scholar 

  123. Donkers JM, Zehnder B, van Westen GJP et al (2017) Reduced hepatitis B entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP. Sci Rep 7:15307

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  124. Yurdaydin C, Keskin O, Kalkin C et al (2017) Optimizing lonafarnib treatment for the management of chronic delta virus: the LOWR HDV-1 study. Hepatology 67(4):1224–1236. https://doi.org/10.1002/hep.29658.

    Article  Google Scholar 

  125. Dusheiko G (2018) A shift in thinking to reduce mother-to-infant transmission of hepatitis B. N Engl Med J 378:952–953

    Article  Google Scholar 

  126. Keane E, Funk AL, Shimakawa Y (2016) Systematic review with meta-analysis: the risk of mother-to-child transmission of hepatitis B virus transmission in sub-Saharan Africa. Aliment Pharmacol Ther 44:1005–1017

    Article  CAS  PubMed  Google Scholar 

  127. Chen HL, Lin LH, Hu FC et al (2012) Effects of maternal screening and universal immunization to prevent mother-to-infant transmission of HBV. Gastroenterology 142:773

    Article  PubMed  Google Scholar 

  128. Jourdain G, Ngo-Giang-Huong N, Harrison L et al (2018) Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. N Engl J Med 378:911–933

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada

    I. W. Fong

Authors
  1. I. W. Fong
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Fong, I.W. (2020). Major Advances in Hepatitis C Treatment but Not Hepatitis B. In: Current Trends and Concerns in Infectious Diseases. Emerging Infectious Diseases of the 21st Century. Springer, Cham. https://doi.org/10.1007/978-3-030-36966-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-36966-8_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-36965-1

  • Online ISBN: 978-3-030-36966-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation